Month: December 2022

Xentuzumab is a Monoclonal Antibody That Targets IGF Ligands IGF1 and IGF2

IGF, an insulin-like growth factor, regulates cell growth, proliferation, and survival. The IGF system is made up of IGF1, IGF2, insulin, and corresponding receptors. It transmits abnormal signals to cause a variety of cancers. One that stands out is castration-resistant prostate cancer. IGF can either up-regulate IGF-binding proteins or...

TD1092 is a pan-IAP degrader, degrades cIAP1, cIAP2, and XIAP

Apoptosis inhibitor proteins (IAP) represent a group of caspases and negative regulators of cell death. Particularly, the IAP protein family prevents cell death by binding to and inhibiting active caspases and is negatively regulated by IAP-binding proteins. In addition to cell death, IAP also acts as an innate immune...

MMRi62, a Ferroptosis Inducer Targeting MDM2-MDM4

MDM2 and MDM4 have established cancer drug targets. Additionally, they are also inhibitors of p53 activity and are amplified in many cancer types. In particular, the targeting of MDM2–p53 interactions is a novel strategy that is pursued to unleash the antitumor activity of p53. Furthermore,  there needs to cover...

SJ988497, a PROTAC JAK2 Degrader, used for Acute Lymphoblastic Leukemia Research

CRLF2-rearranged (CRLF2r) acute lymphoblastic leukemia (ALL) is relevant with a poor outcome in children and adults. CRLF2r-ALL accounts for more than half of Philadelphia chromosome-like (Ph-like) ALL. Noticeably, the overexpression of CRLF2 activates JAK-STAT and parallel signaling pathways. However, small molecules inhibiting JAKs are variable and limited. Importantly, Using...

Ganitumab (AMG 479) is an IGF1R mAb for Cancer Research

Insulin-like growth factor 1 (IGF-1) receptor is a transmembrane receptor. Specifically, it belongs to a large class of tyrosine kinase receptors. This receptor mediates the action of IGF-1, a polypeptide protein hormone with a molecular structure similar to insulin. Besides, IGF-1 plays an important role in the growth and...